We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FRST:NASDAQPrimis Financial Corp. Analysis

Data as of 2026-04-04 - not real-time

$13.36

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Primis Financial (FRST) is trading at $13.36, comfortably above its 20‑day SMA (≈$13.00) but just shy of the 50‑day SMA (≈$13.44), indicating a neutral price stance with a slight bullish tilt. The RSI sits at 56, well within the non‑overbought zone, while the MACD histogram turned positive, signaling emerging upside momentum backed by increasing volume. Valuation multiples are exceptionally cheap – a trailing P/E of 5.4 versus an industry average of 16.6 and a P/B of 0.78 – yet the discounted cash‑flow model caps fair value near $9.0, suggesting the market may be pricing in growth expectations. The company delivers strong profitability (operating margin >50%, profit margin ~29%) and a healthy ROE of ~15%, complemented by a 3% dividend yield and a modest 16% payout ratio, underscoring dividend sustainability. Insider sentiment is positive, with two directors purchasing a combined 2,975 shares in the past month, reinforcing confidence in the near‑term outlook. Volatility remains elevated at ~22% over the past 30 days, but a beta below 1 (≈0.79) tempers systematic risk. Overall, FRST presents a blend of value appeal, solid earnings, and dividend income, while technical signals hint at limited upside toward the $13.52 resistance level.
Given the DCF gap and a modest upside estimate of ~21%, the stock appears fairly valued at current levels. The combination of strong cash flow, low leverage, and regional bank fundamentals supports a medium‑term buy thesis, though investors should monitor sector‑wide interest‑rate dynamics and regulatory developments that could affect regional lenders.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD histogram with rising volume
  • Insider purchases signal confidence
  • Price near support with upside to resistance

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong operating margins and ROE
  • Attractive valuation multiples versus peers
  • Sustainable 3% dividend yield

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • DCF fair value below current price
  • Potential sector headwinds from interest‑rate shifts
  • Stable cash flow and low beta reduce systemic risk

Key Metrics & Analysis

Financial Health

Revenue Growth1259.20%
Profit Margin29.08%
P/E Ratio5.4
ROE14.68%
ROA1.49%
P/B Ratio0.8
Op. Cash Flow$10.8M
Industry P/E16.6

Technical Analysis

TrendNeutral
RSI56.0
Support$12.44
Resistance$13.52
MA 20$13.00
MA 50$13.44
MA 200$11.88
MACDBullish
VolumeIncreasing
Fear & Greed Index78.8

Valuation

Fair Value$9.03
Target Price$16.13
Upside/Downside20.70%
GradeFair
TypeBlend
Dividend Yield3.00%

Risk Assessment

Beta0.79
Volatility21.75%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.